A Phase 2/3 interventional study of HL-1186 and HL-1186 placebo in Postoperative Pain, sponsored by Shanghai Huilun Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by Shanghai Huilun Pharmaceutical Co., Ltd. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 248 studies in Pain, Postoperative with a site in China — 78 open to participants now, 80 under way, 3 of them phase 3. Pain, Postoperative · China.
Among the 248 studies in Pain, Postoperative with a site in China, this one is the 20th largest by planned enrollment of the 205 interventional ones that give a count, is one of 35 that started in 2026, is one of 5 in phase 2/3, reaches primary completion later than 43 of the 79 other live ones, and was the 238th registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.
Browse Pain, Postoperative studies →78 of the 248 studies in Pain, Postoperative with a site in China are open now. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–80
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 18–90
Huazhong University of Science and Technology · Sites in China
Ages 18–80
Shanghai 6th People's Hospital · Sites in China
Ages 18–60
Tianjin First Central Hospital · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
248 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 21 · Phase 3 13 · Phase 4 67
First in 2004; this study’s year is marked. 35 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 330 is above the median of 75 across 4,829 interventional studies indexed under Pain, Postoperative.
Median enrollment 132 across the 205 interventional studies, 350 across the 43 observational. Of the 121 that completed or were terminated, 6 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 248 have an industry lead sponsor. The 10 most frequent:
Shanghai Huilun Pharmaceutical Co., Ltd. is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Shanghai Huilun Pharmaceutical Co., Ltd. has 2 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
21 of the studies in Pain, Postoperative with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07331441Jun ZhangExternal Oblique Intercostal Plane Block for Postoperative Analgesia After Major Upper Abdominal Surgery | 2026-11-25 |
| NCT07412223Xiangya Hospital of Central South UniversityEffect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery | 2026-12-01 |
| NCT07653932Tongji HospitalPerioperative Quantitative Sensory Testing and Incision Pain Mapping in Thoracic Surgery | 2026-12-31 |
| NCT07519109CSPC Ouyi Pharmaceutical Co., Ltd.Study Evaluating the Safety, Efficacy and Pharmacokinetics of SYH9089 Injection in Patients Undergoing Abdominal Surgery. | 2026-12-31 |
| NCT06320041The Fourth Affiliated Hospital of Zhejiang University School of MedicineEfficacy and Safety of Oliceridine for Moderate to Severe Acute Pain After Orthopedic Surgery | 2026-12-31 |
Add all 21 to your calendar (.ics) → With an account.
Among the 248 studies in Pain, Postoperative with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial is a multiple-center, randomized, double-blind, placebo- and active-controlled parallel-group Phase II/III clinical trial, to evaluate the efficacy and safety of HL-1186 Tablets for Postoperative Analgesia in Abdominal Surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized to either the HL-1186 groups, placebo group or active-comparator group, and administer study drug every 6 hours
Drug: HL-1186 · Drug: Oxycodone-Acetaminophen Matching Placebo
Participants will be randomized to either the HL-1186 groups, placebo group or active-comparator group, and administer study drug every 6 hours
Drug: HL-1186 · Drug: HL-1186 placebo · Drug: Oxycodone-Acetaminophen Matching Placebo
Participants will be randomized to either the HL-1186 groups, placebo group or active-comparator group, and administer study drug every 6 hours
Drug: HL-1186 placebo · Drug: Oxycodone-Acetaminophen
Participants will be randomized to either the HL-1186 groups, placebo group or active-comparator group, and administer study drug every 6 hours
Drug: HL-1186 placebo · Drug: Oxycodone-Acetaminophen Matching Placebo
HL-1186 tablet for oral administration.
HL-1186 placebo tablet for oral administration.
Oxycodone-Acetaminophen for oral adminstration.
Oxycodone-Acetaminophen Matching Placebo for oral adminstration.
SPID48
SPID48: Time-weighted Sum of the Pain Intensity Difference (SPID) as recorded on an NRS (Numeric Rating Scale, 0 =no pain to 10 =worst possible pain) at rest 0 to 48 hours after the first dose of study drug. The score range was -480 (worst score) to 480 (best score).
Time frame: 0 to 48 hours
Number of participants with treatment-related adverse events
Time frame: 0-9 days
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Oct 2026, 5 months after the start.
Of 52 phase 2/3 interventional studies under Pain, Postoperative, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 5 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HL-1186
Shanghai Huilun Pharmaceutical Co., Ltd.